Yonsei medical journal
-
Yonsei medical journal · Oct 2020
Randomized Controlled TrialA New Thermo-Responsive Hyaluronic Acid Sol-Gel to Prevent Intrauterine Adhesions after Hysteroscopic Surgery: A Randomized, Non-Inferiority Trial.
To investigate the efficacy and safety of a newly developed thermo-responsive sol-gel, ABT13107, for reducing the formation of intrauterine adhesions (IUAs) after hysteroscopic surgery. ⋯ ABT13107, a new anti-adhesive barrier containing hyaluronic acid, was not inferior to the highly viscous hyaluronic acid anti-adhesive barrier, Hyalurobarrier® in IUA formation after hysteroscopic surgery (Clinical trial registration No. NCT04007211).
-
Yonsei medical journal · Oct 2020
Real-World Experience with Pembrolizumab Treatment in Patients with Heavily Treated Recurrent Gynecologic Malignancies.
We evaluated the efficacy and safety of pembrolizumab in patients with recurrent gynecologic cancers in real-world practice. ⋯ In real-world practice, pembrolizumab was feasible and effective in heavily treated recurrent gynecologic cancer patients with poor performance status who may not be eligible for enrollment in clinical trials.
-
Yonsei medical journal · Oct 2020
Association between Atrial Fibrillation and Advanced Liver Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease.
Non-alcoholic fatty liver disease (NAFLD) is independently associated with the development of atrial fibrillation (AF). However, the association of AF with advanced liver fibrosis, which is related to all-cause, cardiovascular, and liver-related mortality, has not been established in NAFLD patients. We aimed to investigate the association between AF and advanced liver fibrosis in NAFLD patients. ⋯ AF is independently associated with advanced liver fibrosis in patients with NAFLD.
-
Yonsei medical journal · Oct 2020
Erratum to "Network Analysis of Language Disorganization in Patients with Schizophrenia" by Park SC, et al. (Yonsei Med J 2020; 61(8): 726-730.).
This corrects the article on p. 726 in vol. 61, PMID: 32734737.
-
Yonsei medical journal · Oct 2020
Meta AnalysisTolerability of Alternative Dosing Schedules for Sunitinib: A Systematic Review and Meta-Analysis.
The standard schedule for sunitinib treatment is 4 weeks on and 2 weeks off (4/2) in first-line treatment for metastatic renal cell carcinoma (mRCC). Schedule modifications, including 2 weeks on and 1 week off (2/1), appear to reduce the total number of treatment-related adverse events (TRAEs) without compromising efficacy. Even though TRAEs can qualitatively differ from each other, it is not clear as to what effects a 2/1 schedule has on individual TRAEs. ⋯ This meta-analysis suggests that a 2/1 schedule of sunitinib lowers the risk of fatigue and the occurrence other AEs without compromising efficacy.